

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

| | | | |
|--------------|----|--|--|
| NEWS | 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS | 2 | AUG 06 | CAS REGISTRY enhanced with new experimental property tags |
| NEWS | 3 | AUG 06 | FSTA enhanced with new thesaurus edition |
| NEWS | 4 | AUG 13 | CA/Caplus enhanced with additional kind codes for granted patents |
| NEWS | 5 | AUG 20 | CA/Caplus enhanced with CAS indexing in pre-1907 records |
| NEWS | 6 | AUG 27 | Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB |
| NEWS | 7 | AUG 27 | USPATOLD now available on STN |
| NEWS | 8 | AUG 28 | CAS REGISTRY enhanced with additional experimental spectral property data |
| NEWS | 9 | SEP 07 | STN AnaVist, Version 2.0, now available with Derwent World Patents Index |
| NEWS | 10 | SEP 13 | FORIS renamed to SOFIS |
| NEWS | 11 | SEP 13 | INPADOCDB enhanced with monthly SDI frequency |
| NEWS | 12 | SEP 17 | CA/Caplus enhanced with printed CA page images from 1967-1998 |
| NEWS | 13 | SEP 17 | Caplus coverage extended to include traditional medicine patents |
| NEWS | 14 | SEP 24 | EMBASE, EMBAL, and LEMBASE reloaded with enhancements |
| NEWS | 15 | OCT 02 | CA/Caplus enhanced with pre-1907 records from Chemisches Zentralblatt |
| NEWS | 16 | OCT 19 | BEILSTEIN updated with new compounds |
| NEWS | 17 | NOV 15 | Derwent Indian patent publication number format enhanced |
| NEWS | 18 | NOV 19 | WPIX enhanced with XML display format |
| NEWS | 19 | NOV 30 | ICSD reloaded with enhancements |
| NEWS | 20 | DEC 04 | LINPADOCDB now available on STN |
| NEWS | 21 | DEC 14 | BEILSTEIN pricing structure to change |
| NEWS | 22 | DEC 17 | USPATOLD added to additional database clusters |
| NEWS | 23 | DEC 17 | IMSDRUGCONF removed from database clusters and STN |
| NEWS | 24 | DEC 17 | DGENE now includes more than 10 million sequences |
| NEWS | 25 | DEC 17 | TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment |
| NEWS | 26 | DEC 17 | MEDLINE and LMEEDLINE updated with 2008 MeSH vocabulary |
| NEWS | 27 | DEC 17 | CA/Caplus enhanced with new custom IPC display formats |
| NEWS | 28 | DEC 17 | STN Viewer enhanced with full-text patent content from USPATOLD |
| NEWS | 29 | JAN 02 | STN pricing information for 2008 now available |
| NEWS | 30 | JAN 16 | CAS patent coverage enhanced to include exemplified prophetic substances |
| | | | |
| NEWS EXPRESS | 19 | SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007. | |
| | | | |
| NEWS HOURS | | STN Operating Hours Plus Help Desk Availability | |

NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:26:31 ON 21 JAN 2008

=> file registry
COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 0.21 | 0.21 |

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 12:26:44 ON 21 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JAN 2008 HIGHEST RN 1000368-36-4

DICTIONARY FILE UPDATES: 20 JAN 2008 HIGHEST RN 1000368-36-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10 series\10539546\10539546a.str



chain nodes :
7 14 15 16

ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13

```

chain bonds :
2-8 5-7 6-14 14-15 14-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
5-7 14-15 14-16
exact bonds :
2-8 6-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:27:04 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 88 TO ITERATE

100.0% PROCESSED 88 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1198 TO 2322

PROJECTED ANSWERS: 866 TO 1854


L2 50 SEA SSS SAM L1

=> d scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Pyrazinecarboxamide, 3-amino-6-[3-[(5-chloro-2,3-dihydro-1H-inden-1-yl)amino]methyl]phenyl]-N-methyl- (9CI)

MF C22 H22 Cl N5 O





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>

Uploading C:\Program Files\Stnexp\Queries\10 series\10539546\10539546b.str



```
chain nodes :
7 14 15 16 17
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13
chain bonds :
2-8 5-7 6-14 14-15 14-16 16-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
5-7 14-15 14-16 16-17
exact bonds :
2-8 6-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
```

Match level :


```
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:Atom
```

L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS

L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l3

SAMPLE SEARCH INITIATED 12:28:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 88 TO ITERATE

100.0% PROCESSED 88 ITERATIONS
SEARCH TIME: 00.00.01

26 ANSWERS


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1198 TO 2322
PROJECTED ANSWERS: 215 TO 825

L4 26 SEA SSS SAM L3

=> d scan

L4 26 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[2-(trifluoromethoxy)phenyl]sulfonyl]amino]methyl]phenyl]- (9CI)
MF C24 H25 F3 N6 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 13 full
FULL SEARCH INITIATED 12:28:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1789 TO ITERATE


100.0% PROCESSED 1789 ITERATIONS
SEARCH TIME: 00.00.01

572 ANSWERS

L5 572 SEA SSS FUL L3

=> d scan

L5 572 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyrazinecarboxamide, 3-amino-6-[2,6-dimethyl-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-N-3-pyridinyl- (9CI)
MF C25 H31 N7 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 179.74 | 179.95 |

FILE 'CAPLUS' ENTERED AT 12:29:19 ON 21 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 21 Jan 2008 VOL 148 ISS 4
FILE LAST UPDATED: 20 Jan 2008 (20080120/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l5


L6 9 L5

=> d l6 1-9 ibib abs hitstr

L6 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1029856 CAPLUS
DOCUMENT NUMBER: 147:315127
TITLE: Glycogen synthase kinase 3 (GSK-3) inhibitors for the
treatment of osteoporosis
INVENTOR(S): Berg, Anna-Lena; Bhat, Ratan
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 30pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|-------------------|-----------------|------------|
| ----- | ---- | ----- | ----- | ----- |
| WO 2007102770 | A1 | 20070913 | WO 2007-SE216 | 20070306 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| US 2007213322 | A1 | 20070913 | US 2007-683458 | 20070308 |
| PRIORITY APPLN. INFO.: | | | US 2006-780252P | P 20060308 |
| OTHER SOURCE(S): | | MARPAT 147:315127 | | |

GI




AB The present invention relates to a new use of a compound of the formula (I) wherein R1 is NH2, piperazin-1-yl, 4-methylpiperazin-1-yl, 4-methyl-1,4-diazepan-1-yl or 4-ethylpiperazin-1-yl; R2 is hydrogen, fluoro, CH3, CH2CH3, OCH3, CF3 or OCF3; R3 is hydrogen, CH3 or fluoro; as a free base or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention and/or treatment of bone-related disorders, osteoporosis and increasing bone formation and bone mineral d. The present invention further relates to a method of prevention and/or treatment of these disorders.

IT 486423-12-5, 3-Amino-6-[3-ethyl-4-[[4-methylpiperazin-1-yl]sulfonyl]phenyl]-N-pyridin-3-ylpyrazine-2-carboxamide
 486423-13-6, 3-Amino-6-[4-[[4-methylpiperazin-1-yl]sulfonyl]-3-[trifluoromethoxy]phenyl]-N-pyridin-3-ylpyrazine-2-carboxamide
 486423-25-0, 3-Amino-6-[4-[[4-ethylpiperazin-1-yl]sulfonyl]phenyl]-N-pyridin-3-ylpyrazine-2-carboxamide 486424-22-0,
 3-Amino-6-[2,5-difluoro-4-[[4-methylpiperazin-1-yl]sulfonyl]phenyl]-N-pyridin-3-ylpyrazine-2-carboxamide 486424-23-1,
 3-Amino-6-[3-fluoro-4-[[4-methylpiperazin-1-yl]sulfonyl]phenyl]-N-pyridin-3-ylpyrazine-2-carboxamide 486424-24-2, 3-Amino-6-[3-methyl-4-[[4-methylpiperazin-1-yl]sulfonyl]phenyl]-N-pyridin-3-ylpyrazine-2-carboxamide 486424-27-5, 3-Amino-6-[2-methyl-4-[[4-methylpiperazin-1-yl]sulfonyl]phenyl]-N-pyridin-3-ylpyrazine-2-carboxamide 486424-43-5, 3-Amino-6-[2-fluoro-4-[[4-methylpiperazin-1-yl]sulfonyl]phenyl]-N-pyridin-3-ylpyrazine-2-carboxamide 487034-72-0b, sulfonyl derivs. 742053-70-9,
 3-Amino-6-[5-fluoro-2-methyl-4-[[4-methylpiperazin-1-yl]sulfonyl]phenyl]-N-pyridin-3-ylpyrazine-2-carboxamide 766504-06-7,
 3-Amino-6-[4-[[4-methyl-1,4-diazepan-1-yl]sulfonyl]phenyl]-N-pyridin-3-ylpyrazine-2-carboxamide 773050-68-3, 3-Amino-6-[2,5-dimethyl-4-[[4-methylpiperazin-1-yl]sulfonyl]phenyl]-N-pyridin-3-ylpyrazine-2-carboxamide 947701-64-6, 3-Amino-6-[4-[[4-methylpiperazin-1-yl]sulfonyl]-3-[trifluoromethyl]phenyl]-N-pyridin-3-ylpyrazine-2-carboxamide

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (glycogen synthase kinase 3 (GSK-3) inhibitors for the treatment of osteoporosis)


RN 486423-12-5 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[3-ethyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (CA INDEX NAME)




RN 486423-13-6 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]-3-(trifluoromethoxy)phenyl]-N-3-pyridinyl- (CA INDEX NAME)




RN 486423-25-0 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[4-[(4-ethyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (CA INDEX NAME)




RN 486424-22-0 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (CA INDEX NAME)




RN 486424-23-1 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[3-fluoro-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (CA INDEX NAME)




RN 486424-24-2 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[3-methyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (CA INDEX NAME)




RN 486424-27-5 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[2-methyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (CA INDEX NAME)




RN 486424-43-5 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[2-fluoro-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (CA INDEX NAME)




RN 487034-72-0 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-phenyl-N-3-pyridinyl- (CA INDEX NAME)




RN 742053-70-9 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[5-fluoro-2-methyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (CA INDEX NAME)




RN 766504-06-7 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)sulfonyl]phenyl]-N-3-pyridinyl- (CA INDEX NAME)



RN 773050-68-3 CAPLUS


CN 2-Pyrazinecarboxamide, 3-amino-6-[2,5-dimethyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (CA INDEX NAME)



RN 947701-64-6 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]-3-(2,5-dimethylphenyl)phenyl]-N-3-pyridinyl- (CA INDEX NAME)


(trifluoromethyl)phenyl]-N-3-pyridinyl- (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:962046 CAPLUS
 DOCUMENT NUMBER: 143:266952
 TITLE: Preparation of bipyridyl amides as modulators of metabotropic glutamate receptor-5
 INVENTOR(S): Bonnefous, Celine; Kamenecka, Theodore M.; Vernier, Jean-Michel
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., '79 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|--|------------------|------------|
| WO 2005079802 | A1 | 20050901 | WO 2005-US3952 | 20050209 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| AU 2005215379 | A1 | 20050901 | AU 2005-215379 | 20050209 |
| CA 2555402 | A1 | 20050901 | CA 2005-2555402 | 20050209 |
| EP 1715867 | A1 | 20061102 | EP 2005-713111 | 20050209 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | |
| CN 1933838 | A | 20070321 | CN 2005-80004732 | 20050209 |
| JP 2007524682 | T | 20070830 | JP 2006-553189 | 20050209 |
| IN 2006DN04346 | A | 20070713 | IN 2006-DN4346 | 20060727 |
| US 2007149547 | A1 | 20070628 | US 2006-589407 | 20060811 |
| PRIORITY APPLN. INFO.: | | | US 2004-544627P | P 20040212 |
| | | | WO 2005-US3952 | W 20050209 |
| OTHER SOURCE(S): | | CASREACT 143:266952; MARPAT 143:266952 | | |
| GI | | | | |



I



II

AB The title compds. I [X = N, C; Y = N, C, C(halo); R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, aryl, etc.; R3 = aryl, halo, alkyl, etc.; R2 and R3 may be joined together with the atoms to which they are attached to form a (un)saturated 4-7 membered ring containing 0-2 heteroatoms selected

from

O, S and N; R4 = aryl, heteroaryl, halo, etc.] which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases, were prepared. Thus, amidation of pyridin-2-amine with 3-amino-5,6-diphenylpyrazine-2-carboxylic acid afforded the amide II. The exemplified compds. I have mGluR5 inhibitory activity as shown by inhibition at 10 μ M or less in the calcium flux assay or 100 μ M or less or less in the PI assay. The invention is also directed to pharmaceutical compns. comprising compds. I.


IT 863908-42-3P 863908-69-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bipyridyl amides as modulators of metabotropic glutamate receptor-5)


RN 863908-42-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-phenyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 863908-69-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(2-cyanophenyl)-N-2-pyridinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on SIN

ACCESSION NUMBER: 2005:216619 CAPLUS

DOCUMENT NUMBER: 142:297864

TITLE: Preparation of aniline derivatives and related compounds as c-kit modulators

INVENTOR(S): Cheng, Wei; Co, Erick Wang; Kim, Moon Hwan; Klein, Rhett Ronald; Le Donna, T.; Lew, Amy; Nuss, John M.; Xu, Wei; Bajjalieh, William

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 169 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 2005020921 | A2 | 20050310 | WO 2004-US28001 | 20040827 |
| WO 2005020921 | A3 | 20051006 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| AU 2004268621 | A1 | 20050310 | AU 2004-268621 | 20040827 |
| CA 2536954 | A1 | 20050310 | CA 2004-2536954 | 20040827 |
| EP 1663204 | A2 | 20060607 | EP 2004-782473 | 20040827 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | |
| JP 2007504160 | T | 20070301 | JP 2006-524905 | 20040827 |
| PRIORITY APPLN. INFO.: | | | US 2003-499224P | P 20030829 |
| | | | WO 2004-US28001 | W 20040827 |

OTHER SOURCE(S): MARPAT 142:297864

GI



AB Compds. I [wherein ring A is a five- to fourteen-membered heteroaryl; R¹, R² and R³ are H, halo, trihalomethyl, cyano, nitro, etc.; L¹ is a single bond, (un)substituted alkylene, O, CH₂O, etc.; ring B is five- to ten-membered aryl or heterocyclyl; ring C is five- to ten-membered (hetero)aryl; L² is alkylene, alkylidene, alkylidyne, etc.; with some limitations and exclusions, and pharmaceutically acceptable salts, hydrates or prodrugs thereof], as exemplified by carbonyl compds. of anilines, were prepared as c-Kit kinase modulators. For example, 3-aminophenoxyacetic acid, which was obtained from the corresponding nitro compound in 76% yield via catalytic hydrogenation, was treated with HC(OEt)₃ and NaN₃ in AcOH followed by NaNO₂/HCl to give a tetrazole in 61% yield. This acid was coupled with 5-amino-2-chlorobenzotrifluoride in the presence of HATU to afford acetamide II in 46% yield, which showed inhibition against c-Kit kinase with a IC₅₀ of < 50 nM. Therefore, I and pharmaceutical compns. thereof are useful for modulating c-Kit kinase activity and for treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities.


IT 847606-88-6P 847608-93-9P 847608-94-0P
847608-95-1P 847608-96-2P 847609-35-2P
847609-36-3P 847609-39-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(modulator; preparation of anilines and related compds. as C-kit modulators)

RN 847606-88-6 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-3-piperidinyl- (9CI) (CA INDEX NAME)



RN 847608-93-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]pyrazinyl]carbo
nyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847608-94-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847608-95-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[4-[[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]pyrazinyl]carbo
nyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 847608-96-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidiny- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 847609-35-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]pyrazinyl]carboxyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 847609-36-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]pyrazinyl]carboxyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 847609-39-6 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methylphenyl]-N-3-piperidinyl- (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:759828 CAPLUS

DOCUMENT NUMBER: 141:260774

TITLE: Preparation of pyrazinecarboxamide compounds as inhibitors of transforming growth factor (TGF) signaling pathway

INVENTOR(S): Munchhof, Michael J.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 26 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| US 2004180905 | A1 | 20040916 | US 2004-798198 | 20040310 |
| US 7199123 | B2 | 20070403 | | |
| CA 2517720 | A1 | 20040923 | CA 2004-2517720 | 20040223 |
| WO 2004080982 | A1 | 20040923 | WO 2004-IB581 | 20040223 |


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 EP 1606267 A1 20051221 EP 2004-713617 20040223
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2004008251 A 20060301 BR 2004-8251 20040223
 JP 2006519833 T 20060831 JP 2006-506288 20040223
 PRIORITY APPLN. INFO.: US 2003-453784P P 20030311
 WO 2004-IB581 W 20040223

OTHER SOURCE(S): MARPAT 141:260774
 GI



I



II


AB Pyrazine compds. of formula I [R = (substituted) Ph, heterocyclyl, heteroaryl, aryl; R1 = H, R2 = alkyl, cycloalkyl, aryl, heteroaryl, etc.; NR2R2 = (substituted) heterocyclyl, heteroaryl] are prepared The compds. are potent inhibitors of transforming growth factor (TGF)- β signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases. Thus, II was prepared, and had IC50 of 1.19 μ M.

IT 625459-32-7P 625459-38-3P 625469-79-6P
 756521-55-8P 756521-56-9P 756521-61-6P
 756521-62-7P 756521-64-9P 756521-68-3P
 756521-69-4P 756521-70-7P 756521-74-1P
 756521-75-2P 756521-76-3P 756521-79-6P
 756521-80-9P 756521-81-0P 756521-84-3P
 756521-85-4P 756521-86-5P 756521-87-6P
 756521-91-2P 756521-92-3P 756521-96-7P
 756522-00-6P 756522-03-9P 756522-17-5P
 756522-20-0P 756522-23-3P 756522-32-4P
 756522-45-9P 756522-46-0P 756522-47-1P
 756522-86-8P 756522-88-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazinecarboxamides as inhibitors of TGF- β signaling pathway)

RN 625459-32-7 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-cyclopentyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 625459-38-3 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-cyclohexyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 625469-79-6 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N,6-diphenyl- (9CI) (CA INDEX NAME)




RN 756521-55-8 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-cycloheptyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 756521-56-9 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-(2,3-dihydro-1H-inden-1-yl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 756521-61-6 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-(4-chlorophenyl)-N-cyclopentyl- (9CI) (CA
 INDEX NAME)



RN 756521-62-7 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-(4-chlorophenyl)-N-cycloheptyl- (9CI) (CA
 INDEX NAME)




RN 756521-64-9 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-(4-chlorophenyl)-N-cyclohexyl- (9CI) (CA
 INDEX NAME)




RN 756521-68-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(3-chlorophenyl)-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 756521-69-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(3-chlorophenyl)-N-cycloheptyl- (9CI) (CA INDEX NAME)




RN 756521-70-7 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-(3-chlorophenyl)-N-cyclohexyl- (9CI) (CA INDEX NAME)




RN 756521-74-1 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-(2-chlorophenyl)-N-cyclopentyl- (9CI) (CA
 INDEX NAME)




RN 756521-75-2 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-(2-chlorophenyl)-N-cycloheptyl- (9CI) (CA
 INDEX NAME)




RN 756521-76-3 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-(2-chlorophenyl)-N-cyclohexyl- (9CI) (CA
 INDEX NAME)




RN 756521-79-6 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-cyclohexyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 756521-80-9 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-cycloheptyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 756521-81-0 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-cyclohexyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 756521-84-3 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-cyclopentyl-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 756521-85-4 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-cycloheptyl-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 756521-86-5 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-cyclohexyl-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 756521-87-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(4-methoxyphenyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 756521-91-2 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-(2,3-dihydro-1H-inden-1-yl)-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 756521-92-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[(3S)-hexahydro-2-oxo-1H-azepin-3-yl]-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 756521-96-7 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-(4-methoxyphenyl)-N-[1-(phenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 756522-00-6 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-[(1R,2S)-2-(hydroxymethyl)cyclohexyl]-6-(4-methoxyphenyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 756522-03-9 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-6-(4-methoxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 756522-17-5 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-phenyl-N-[1-(phenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 756522-20-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[(1R,2S)-2-(hydroxymethyl)cyclohexyl]-6-phenyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 756522-23-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-6-phenyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 756522-32-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-6-(4-methylphenyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 756522-45-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(4-chlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 756522-46-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(3-chlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 756522-47-1 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-(2-chlorophenyl)-N-[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 756522-86-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-cyclopentyl-6-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 756522-88-0 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-[(3S)-hexahydro-2-oxo-1H-azepin-3-yl]-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on SIN
 ACCESSION NUMBER: 2004:534194 CAPLUS
 DOCUMENT NUMBER: 141:89114
 TITLE: Preparation of novel 3-aminopyrazine-2-carboxamides having selective inhibiting effect at GSK3
 INVENTOR(S): Berg, Stefan; Hellberg, Sven
 PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Soederman, Peter
 SOURCE: PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2004055006 | A1 | 20040701 | WO 2003-SE1956 | 20031215 |
| WO 2004055006 | A8 | 20050630 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,


CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003287136 A1 20040709 AU 2003-287136 20031215
 EP 1575939 A1 20050921 EP 2003-781205 20031215
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2006516124 T 20060622 JP 2004-560224 20031215
 US 2006173014 A1 20060803 US 2005-539546 20050616

PRIORITY APPLN. INFO.: SE 2002-3752 A 20021217
 WO 2003-SE1956 W 20031215

OTHER SOURCE(S): MARPAT 141:89114
 GI



AB The title compds. [I; Z = N; X = N; Y = CONR5; P = Ph; Q = Ph or 5-6 membered aromatic heteroarom. ring containing one or more heteroatoms selected from N, O, S; R = alkyl(SO2)NR1R2, alkylCONR1R2, OalkylNR1R2 (wherein R1, R2 = H, alkyl, 5-6 membered heterocyclyl, etc.; NR1R2 = 5-6 membered heterocyclyl); R3, R4 = halo, NO2, CF3, etc.; m, n = 0-1; R5 = H; as a free base or a pharmaceutically acceptable salt], were prepared and formulated. Thus, treating 4-bromo-N-[(1R)-2-methoxy-1-methylethyl]benzenesulfonamide with n-butyllithium and triisopropyl borate in THF followed by reacting the intermediate with 3-amino-6-bromo-N-(pyridin-3-yl)pyrazine-2-carboxamide in the presence of Pd(dppf)Cl2, and Na2CO3 in THF (preps. of reactants given) afforded 35% 3-amino-6-[4-(((1R)-2-methoxy-1-methylethylamino)sulfonyl)phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide hydrochloride. Typical Ki values for the compds. I are in the range of about 0.001 to about 10,000 nM in GSK-3 β assay.

IT 486423-43-2P 714237-12-4P 714237-13-5P
 714237-14-6P 714237-15-7P 714237-16-8P
 714237-17-9P 714237-18-0P 714237-19-1P
 714237-20-4P 714237-21-5P 714237-22-6P
 714237-23-7P 714237-24-8P 714237-25-9P
 714237-26-0P 714237-27-1P 714237-28-2P
 714237-29-3P 714237-30-6P 714237-31-7P
 714237-32-8P 714237-33-9P 714237-34-0P
 714237-35-1P 714237-36-2P 714237-37-3P
 714237-38-4P 714237-39-5P 714237-40-8P
 714237-41-9P 714237-43-1P 714237-44-2P
 714237-45-3P 714237-46-4P 714237-47-5P
 714237-48-6P 714237-49-7P 714237-50-0P
 714237-51-1P 714237-52-2P 714237-53-3P

714237-54-4P 714237-55-5P 714237-56-6P


714237-57-7P 714237-58-8P 714237-68-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel 3-aminopyrazine-2-carboxamides having selective inhibiting effect at GSK3)

RN 486423-43-2 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 714237-12-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[(1R)-2-methoxy-1-methylethyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714237-13-5 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[[[(1S)-2-methoxy-1-methylethyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714237-14-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3-nitrophenyl)-6-[4-(1-pyrrolidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 714237-15-7 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-(1-pyrrolidinylsulfonyl)phenyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)



RN 714237-16-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(2-methoxyphenyl)-6-[4-(4-methyl-1-


piperazinyl)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 714237-17-9 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-(4-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 714237-18-0 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-[2-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 714237-19-1 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-[3-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 714237-20-4 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-(3-cyanophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 714237-21-5 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-(2-bromophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 714237-22-6 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-(3-bromophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HC1

RN 714237-23-7 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-1H-pyrazol-3-yl-, monohydrochloride (9CI)
(CA INDEX NAME)




● HC1

RN 714237-24-8 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-[4-(aminocarbonyl)-1H-pyrazol-3-yl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 714237-25-9 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-1H-imidazol-2-yl-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 714237-26-0 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 714237-27-1 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[(1-ethyl-3-piperidinyl)amino]sulfonyl]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 714237-28-2 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[(bis(2-methoxyethyl)amino)sulfonyl]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 714237-29-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[(3-methylbutyl)amino]sulfonyl]phenyl]-N-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 714237-30-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[(1S)-2-methoxy-1-methylethyl]amino]carbonyl]phenyl]-N-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714237-31-7 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 714237-32-8 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-(3-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 714237-33-9 CAPLUS


CN Pyrazinecarboxamide, N-(3-(4-methoxyphenyl)-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 714237-34-0 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 714237-35-1 CAPLUS

CN Pyrazinecarboxamide, N-[3-(acetylamino)phenyl]-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-36-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[3-(aminosulfonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 714237-37-3 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[[(2-ethoxyethyl)amino]sulfonyl]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 714237-38-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 714237-39-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[(1-ethyl-3-piperidinyl)amino]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 714237-40-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[bis(2-methoxyethyl)amino]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 714237-41-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[(3-methylbutyl)amino]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 714237-43-1 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-(3-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 714237-44-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[(1R)-2-methoxy-1-methylethyl]amino]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714237-45-3 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[[[(1S)-2-methoxy-1-methylethyl]amino]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714237-46-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[(2-ethoxyethyl)amino]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 714237-47-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(4-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-48-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[2-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-49-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[3-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-50-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3-cyanophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-51-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(2-bromophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-52-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3-bromophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-53-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)




RN 714237-54-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[4-(aminocarbonyl)-1H-pyrazol-3-yl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 714237-55-5 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-1H-imidazol-2-yl-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 714237-56-6 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[[[(1S)-2-methoxy-1-methylethylamino]carbonyl]phenyl]-N-3-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714237-57-7 CAPLUS

CN Pyrazinecarboxamide, N-(3-acetylphenyl)-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-58-8 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 714237-68-0 CAPLUS
CN Pyrazinecarboxamide, 3-amino-N-(2-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



IT 486424-13-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel 3-aminopyrazine-2-carboxamides having selective inhibiting effect at GSK3)
RN 486424-13-9 CAPLUS
CN Benzoic acid, 4-[5-amino-6-[(3-pyridinylamino)carbonyl]pyrazinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:534193 CAPLUS
DOCUMENT NUMBER: 141:89113
TITLE: Preparation of novel pyrazinamine or pyridin-2-amine derivatives having selective inhibiting effect at GSK3
INVENTOR(S): Berg, Stefan; Hellberg, Sven; Soederman, Peter
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|

| | | | | |
|---|----|----------|------------------|------------|
| WO 2004055005 | A1 | 20040701 | WO 2003-SE1955 | 20031215 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2508042 | A1 | 20040701 | CA 2003-2508042 | 20031215 |
| AU 2003287135 | A1 | 20040709 | AU 2003-287135 | 20031215 |
| AU 2003287135 | B2 | 20070125 | | |
| EP 1575938 | A1 | 20050921 | EP 2003-781204 | 20031215 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003017294 | A | 20051108 | BR 2003-17294 | 20031215 |
| CN 1729185 | A | 20060201 | CN 2003-80106663 | 20031215 |
| JP 2006513180 | T | 20060420 | JP 2004-560223 | 20031215 |
| MX 2005PA06243 | A | 20050819 | MX 2005-PA6243 | 20050610 |
| US 2006116362 | A1 | 20060601 | US 2005-539543 | 20050616 |
| NO 2005003460 | A | 20050812 | NO 2005-3460 | 20050715 |
| ZA 2005004617 | A | 20060329 | ZA 2005-4617 | 20060116 |
| PRIORITY APPLN. INFO.: | | | SE 2002-3754 | A 20021217 |
| | | | WO 2003-SE1955 | W 20031215 |

OTHER SOURCE(S): MARPAT 141:89113

GI



AB The title compds. [I; Z = N; X = CH, N; Y = CONR₅, NR₅CO, SO₂NR₅, etc.; P = Ph or 5-6 membered heteroarom. ring containing one or more heteroatoms selected from N, O or S (optionally fused); Q = Ph or 5-6 membered aromatic heterocyclic ring containing one or more N atoms (optionally fused); R = alkylNR₁₀R₁₁, alkylazetidene (wherein R₁₀ = H, alkyl, alkenyl, alkynyl, alkylcycloalkyl, alkylaryl, alkylheteroaryl or alkylNR₈R₉; R₁₁ = alkylNR₈R₉, alkylcycloalkyl or alkylheterocycloalkyl; R₈, R₉ = H, alkyl, alkylaryl, etc.); R₃, R₄ = halo, NO₂, CHO, etc.; m, n = 0-4; R₅ = H, alkyl, alkylaryl, etc.; as a free base or a pharmaceutically acceptable salt], were prepared and formulated. Thus, treating N-[3-(4-bromophenyl)propyl]-N,N-dicyclobutylamine with n-butyllithium and triisopropyl borate in THF followed by reaction of the intermediate with 3-amino-6-bromo-N-(pyridin-3-yl)pyrazine-2-carboxamide in the presence of Pd(dppf)Cl₂, and Na₂CO₃ in THF (prepn. of reactants were given) afforded 53% 3-amino-6-[4-[3-(dicyclobutylamino)propyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide hydrochloride. Typical K_i values for the compds. of the present invention are in the range of about 0.001 to about 10,000 nM in GSK-3β assay.


IT 713541-87-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel pyrazinamine or pyridin-2-amine derivs. having selective inhibiting effect at GSK3)

RN 713541-87-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[3-(dicyclobutylamino)propyl]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:892800 CAPLUS

DOCUMENT NUMBER: 139:395950

TITLE: Preparation of substituted pyrazines as protein kinase modulators

INVENTOR(S): Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepf, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Timothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 468 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2003093297 | A2 | 20031113 | WO 2003-US13869 | 20030502 |
| WO 2003093297 | A3 | 20040701 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2484209 A1 20031113 CA 2003-2484209 20030502
 AU 2003234464 A1 20031117 AU 2003-234464 20030502
 EP 1501514 A2 20050202 EP 2003-728690 20030502
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005530760 T 20051013 JP 2004-501436 20030502
 US 2006211709 A1 20060921 US 2005-513081 20050727
 PRIORITY APPLN. INFO.: US 2002-377933P P 20020503
 WO 2003-US13869 W 20030502

OTHER SOURCE(S): MARPAT 139:395950
 GI



AB This invention relates to compds. I [R1 = H, halo, CN, etc.; R2, R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; Z = N, CH; A = CO, CS, C:(NR6), R7 (when A = R7, E does not exist); R6 = H, NO2, CN, etc.; R7 = (un)substituted 5-7 membered heterocyclyl; E = NR8R9, NNR2R3, OR4, etc.; R8 = H, alkyl; R9 = H, heteroarylalkyl, etc.; NR8R9 = (un)substituted 5-7 membered heteroalicycyl; W = 6-10 membered arylene, 5-10 membered heteroarylene; X = a bond, (un)substituted alkylene, O(CH2)2-30, etc.; Y = H, alkyl, aryl, etc.; with provisos] for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compns. containing such compds. Even more specifically, the invention relates to compds. I that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Preparation of representative compds. I is described. Thus, amidation of 3-amino-6-phenylpyrazinecarboxylic acid (preparation given) with benzylamine afforded 67% 3-amino-6-phenyl-N-(phenylmethyl)pyrazine-2-carboxamide which showed IC50 of 10,000 nM or greater against Chk1. Table presenting activity data with respect to Chk1 for over 1000 compds. I is given. Methods of therapeutically or prophylactically using the compds. I and compns. to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amts. of such compds.


IT 625461-86-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of protein kinase modulators)

RN 625461-86-1 CAPLUS

CN Benzoic acid, 3-[5-amino-6-[(cyclopropylamino)carbonyl]pyrazinyl]-, methyl

ester (9CI) (CA INDEX NAME)



| | | | |
|----|--------------|--------------|--------------|
| IT | 625459-28-1P | 625459-29-2P | 625459-30-5P |
| | 625459-32-7P | 625459-38-3P | 625459-46-3P |
| | 625462-18-2P | 625462-19-3P | 625464-78-0P |
| | 625464-93-9P | 625465-07-8P | 625465-09-0P |
| | 625465-89-6P | 625465-90-9P | 625465-91-0P |
| | 625465-94-3P | 625466-05-9P | 625466-30-0P |
| | 625466-31-1P | 625466-32-2P | 625466-33-3P |
| | 625466-34-4P | 625466-35-5P | 625466-41-3P |
| | 625466-45-7P | 625466-51-5P | 625466-53-7P |
| | 625466-54-8P | 625466-55-9P | 625466-56-0P |
| | 625466-57-1P | 625466-58-2P | 625466-59-3P |
| | 625466-60-6P | 625466-61-7P | 625466-62-8P |
| | 625466-71-9P | 625466-72-0P | 625466-73-1P |
| | 625466-74-2P | 625466-75-3P | 625466-82-2P |
| | 625466-83-3P | 625466-84-4P | 625466-85-5P |
| | 625466-86-6P | 625466-87-7P | 625466-88-8P |
| | 625466-89-9P | 625466-98-0P | 625466-99-1P |
| | 625467-00-7P | 625467-01-8P | 625467-02-9P |
| | 625467-03-0P | 625467-04-1P | 625467-06-3P |
| | 625467-07-4P | 625467-08-5P | 625467-10-9P |
| | 625467-12-1P | 625467-18-7P | 625467-19-8P |
| | 625467-20-1P | 625467-21-2P | 625467-23-4P |
| | 625467-24-5P | 625467-25-6P | 625467-35-8P |
| | 625467-36-9P | 625467-40-5P | 625467-41-6P |
| | 625467-43-8P | 625467-44-9P | 625467-45-0P |
| | 625467-46-1P | 625467-47-2P | 625467-48-3P |
| | 625467-50-7P | 625467-51-8P | 625467-52-9P |
| | 625467-54-1P | 625467-55-2P | 625467-56-3P |
| | 625467-57-4P | 625467-59-6P | 625467-62-1P |
| | 625467-63-2P | 625467-65-4P | 625467-66-5P |
| | 625467-71-2P | 625467-72-3P | 625467-73-4P |
| | 625467-79-0P | 625467-80-3P | 625467-81-4P |
| | 625467-82-5P | 625467-83-6P | 625467-84-7P |
| | 625467-85-8P | 625467-86-9P | 625467-87-0P |
| | 625467-88-1P | 625467-89-2P | 625467-90-5P |
| | 625467-91-6P | 625467-92-7P | 625467-93-8P |
| | 625467-94-9P | 625467-95-0P | 625467-96-1P |
| | 625467-97-2P | 625467-98-3P | 625467-99-4P |
| | 625468-00-0P | 625468-01-1P | 625468-02-2P |
| | 625468-03-3P | 625468-04-4P | 625468-06-6P |
| | 625468-07-7P | 625468-08-8P | 625468-09-9P |
| | 625468-10-2P | 625468-11-3P | 625468-12-4P |
| | 625468-13-5P | 625468-14-6P | 625468-15-7P |
| | 625468-16-8P | 625468-17-9P | 625468-18-0P |
| | 625468-19-1P | 625468-20-4P | 625468-21-5P |

625468-22-6P 625468-23-7P 625468-24-8P
 625468-25-9P 625468-26-0P 625468-27-1P
 625468-28-2P 625468-29-3P 625468-30-6P
 625468-31-7P 625468-32-8P 625468-33-9P
 625468-34-0P 625468-37-3P 625468-38-4P
 625468-39-5P 625468-40-8P 625468-41-9P
 625468-42-0P 625468-43-1P 625468-44-2P
 625468-45-3P 625468-46-4P 625468-47-5P
 625468-48-6P 625468-49-7P 625468-50-0P
 625468-51-1P 625468-52-2P 625468-53-3P
 625468-54-4P 625468-55-5P 625468-56-6P
 625468-57-7P 625468-58-8P 625468-59-9P
 625468-60-2P 625468-61-3P 625468-62-4P
 625468-64-6P 625468-65-7P 625468-66-8P
 625468-67-9P 625468-68-0P 625468-69-1P
 625468-70-4P 625468-71-5P 625468-72-6P
 625468-73-7P 625468-74-8P 625468-75-9P
 625468-76-0P 625468-77-1P 625468-78-2P
 625468-86-2P 625468-87-3P 625468-88-4P
 625468-89-5P 625468-90-8P 625468-91-9P
 625468-92-0P 625468-93-1P 625468-94-2P
 625468-95-3P 625468-96-4P 625468-97-5P
 625468-98-6P 625468-99-7P 625469-00-3P
 625469-01-4P 625469-02-5P 625469-03-6P
 625469-04-7P 625469-05-8P 625469-06-9P
 625469-07-0P 625469-08-1P 625469-09-2P
 625469-10-5P 625469-11-6P 625469-12-7P
 625469-13-8P 625469-14-9P 625469-15-0P
 625469-16-1P 625469-17-2P 625469-18-3P
 625469-19-4P 625469-20-7P 625469-21-8P
 625469-22-9P 625469-23-0P 625469-24-1P
 625469-25-2P 625469-26-3P 625469-27-4P
 625469-28-5P 625469-29-6P 625469-30-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of protein kinase modulators)

RN 625459-28-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[(1R)-2,3-dihydro-1H-inden-1-yl]-6-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625459-29-2 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-[(1S)-2,3-dihydro-1H-inden-1-yl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625459-30-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(2,3-dihydro-1H-inden-2-yl)-6-phenyl- (9CI)
(CA INDEX NAME)




RN 625459-32-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-cyclopentyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 625459-38-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-cyclohexyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 625459-46-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-cyclopropyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 625462-18-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-cyclopropyl-6-[3-
[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625462-19-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[(2-chloro-6-
fluorophenyl)methyl]amino]carbonyl]phenyl]-N-cyclopropyl- (9CI) (CA INDEX NAME)



RN 625464-78-0 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-cyclohexyl-6-[3-[[(2,3-dihydro-1H-inden-1-
yl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 625464-93-9 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-cyclopropyl-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625465-07-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 625465-09-0 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 625465-89-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625465-90-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(3R)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625465-91-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-1-(2-furanylcarbonyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625465-94-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-1-(4-pyridinylcarbonyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625466-05-9 CAPLUS

CN Pyrazinecarboxamide, N,N'-1,2-cyclohexanediylbis[3-amino-6-[3-[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 625466-30-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-31-1 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[(3S)-3-[[[3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-1-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625466-32-2 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[(phenylmethyl)amino]carbonyl]phenyl]-N-
 [(3S)-1-(4-piperidinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-33-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[(3S)-3-[[[3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-1-pyrrolidinyl]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-34-4 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-[(3S)-1-[(2R)-2-pyrrolidinylmethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-35-5 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-[(3S)-1-[[4-(dimethylamino)phenyl]methyl]-3-pyrrolidinyl]-6-[3-[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-41-3 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[(phenylmethyl)amino]carbonyl]phenyl]-N-[(3S)-1-(2-pyridinylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-45-7 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-[(3S)-1-ethyl-3-pyrrolidinyl]-6-[3-
 [[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625466-51-5 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-
 yl]amino]carbonyl]phenyl]-N-[(3S)-1-ethyl-3-pyrrolidinyl]- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 625466-53-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidiny-1- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-54-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-55-9 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1R)-1-phenylethyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-56-0 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[(3,4-dihydro-2(1H)-
 isoquinolinyl)carbonyl]phenyl]pyrazinyl]carbonyl]amino]-,
 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625466-57-1 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[(2-
 phenylethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-,
 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-58-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1S)-1-phenylethyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-59-3 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-60-6 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-phenylethyl)amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625466-61-7 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R)-1-phenylethyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-62-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-1-phenylethyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-71-9 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-72-0 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-1-ethyl-3-pyrrolidiny]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-73-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625466-74-2 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-3-piperidiny- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-75-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(1-ethyl-3-piperidiny)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-82-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(4-methoxyphenyl)methyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-83-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[4-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-84-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[2-chloro-6-fluorophenyl]methyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-85-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[4-(methythio)phenyl]methyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-86-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-methoxyphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-87-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-pyrrolidinyl-6-[3-[[[(4-methoxyphenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-88-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-chloro-6-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 625466-89-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(methylthio)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-98-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[4-chlorophenyl)methyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-99-1 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[2-(pyridinylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-00-7 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[3-(pyridin-2-ylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625467-01-8 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[3-(3,4-dihydro-2H-1-benzopyran-4-yl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-02-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-chlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-03-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-pyridinylmethyl)amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-04-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[3-(3-pyridinylmethyl)amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-06-3 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-07-4 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(3R)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-08-5 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-10-9 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(hexahydro-1H-azepin-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-12-1 CAPLUS
 CN 1H-Azepine-1-carboxylic acid, 4-[[[3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]hexahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-18-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625467-19-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-20-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[(3,4-dihydro-2H-1-benzopyran-4-yl)amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-21-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[(2,3-dihydro-3-benzofuranyl)amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-23-4 CAPLUS

CN 1H-Azepine-1-carboxylic acid, 4-[[[3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]hexahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-24-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(hexahydro-1H-azepin-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-25-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[(3aR,8aS)-3a,8a-dihydro-8H-indeno[1,2-d]oxazol-2-yl]phenyl]-N-(hexahydro-1H-azepin-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-35-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-

inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-,
1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-36-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-40-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1-methyl-1-phenylethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-41-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1-methyl-1-phenylethyl)amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-43-8 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]sulfonyl]phenyl]-N-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-44-9 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-1-methyl-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-45-0 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-1-methyl-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625467-46-1 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]methyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-47-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-48-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-pyrrolidinyl-6-[3-[[[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-50-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]sulfonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-51-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-(3-hydroxyphenyl)pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-52-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]sulfonyl]phenyl]-N-(3S)-3-pyrrolidinyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-54-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-pyrrolidinyl-6-[3-[[[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-55-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-pyrrolidinyl-6-[3-[[[(2,3,6-trifluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-56-3 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-pyrrolidinyl-6-[3-[[[(2,3,5-trifluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-57-4 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-bromo-4-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-59-6 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-1-azabicyclo[2.2.2]oct-3-yl-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-62-1 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(2,4-dichlorophenyl)methyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625467-63-2 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(3,4-dichlorophenyl)methyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-65-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-66-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-71-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-methoxyphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-72-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,4-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-73-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-79-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-(aminomethyl)phenyl]-N-(3S)-3-piperidinyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-80-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(3-aminomethylphenyl)-N-(3S)-3-piperidinyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-81-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-(aminomethyl)phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-82-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-fluorophenyl)methyl]amino]carbonyl]

]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-83-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-84-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,1'-biphenyl]-4-ylmethyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-85-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(1,2,3-thiadiazol-5-yl)phenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-86-9 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[2-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-87-0 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1,1'-biphenyl)-2-ylmethyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-88-1 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625467-89-2 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-chloro-2-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-90-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-91-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[2-(2-naphthalenylmethyl)amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-92-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(dimethylamino)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-93-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dihydro-1,4-benzodioxin-5-yl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-94-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[2-(2-thienyl)phenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-95-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-methoxyphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-96-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-dimethoxyphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-97-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-chloro-2-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 625467-98-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-difluoro-4-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 625467-99-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(methylsulfonyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-00-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-01-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-chlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-02-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(5-chloro-2-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 625468-03-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-04-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[[4-(methylthio)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-06-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1,2-diphenylethyl)amino]carbonyl]phenyl]-N-(3S)-3-piperidiny-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-07-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidiny-1-yl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-08-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,5-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-09-9 CAPLUS

CN Benzoic acid, 4-[[[3-[5-amino-6-[(3S)-3-piperidinylamino]carbonyl]pyrazinyl]benzoyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-10-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-bromophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-11-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-bromo-2-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-12-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-bromophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-13-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-14-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-15-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[(3R)-3-pyrrolidinylmethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-16-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[(3R)-3-pyrrolidinylamino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-17-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[2-(1-piperidinyl)ethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-18-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-(phenylethyl)amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-19-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-(methoxyethyl)amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-20-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-iodophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyloxy (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-21-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-chlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyloxy (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-22-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(4-fluorobenzoyl)amino]methyl]phenyl]-
N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-23-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(trifluoromethoxy)benzoyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-24-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(4-chlorobenzoyl)amino]methyl]phenyl]-
N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-25-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[(4-chlorophenyl) acetyl] amino] phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-26-0 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[(2,6-dichlorophenyl) acetyl] amino] phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-27-1 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[(2-chloro-4-chlorophenyl)acetyl]amino]phenyl]-N-(3S)-3-piperidinyloxycarbonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-28-2 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[(2-chloro-4-fluorophenyl)acetyl]amino]phenyl]-N-(3S)-3-piperidinyloxycarbonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-29-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(methylthio)phenyl]acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-30-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,4-dichlorophenyl]acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-31-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(4-chlorophenyl)-2-thienyl]carbonyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-32-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(4-bromobenzoyl)amino]methyl]phenyl]-N-(3S)-3-piperidinyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-33-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-naphthalenylcarbonyl)amino]methyl]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-34-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[2-(4-phenyl-1-piperazinyl)ethoxy]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-37-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-difluorophenyl)acetyl]amino]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-38-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2S)-3-piperidinyl]carbamoyl]amino]phenyl]-N-[(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-39-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[5-(2-chloro-5-(trifluoromethyl)phenyl)-2-furanyl]carbonyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-40-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(dimethylamino)-1-naphthalenyl]carbonyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-41-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(1,2,3-thiadiazol-5-yl)benzoyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-42-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-43-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[4-(dimethylamino)benzoyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-44-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-(2-hydroxyethoxy)phenyl]-N-(3S)-3-

piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-45-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dihydro-5-benzofuranyl)sulfonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 625468-46-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)sulfonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-47-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[(7-quinolinyl)sulfonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-48-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[[(1,1'-biphenyl)-4-ylamino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-49-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[[(4-bromo-2-fluorophenyl)amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-50-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[(3-quinolinylamino)carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-51-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[(6-methoxy-3-benzofuranyl)acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-52-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-53-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-54-4 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-difluorophenyl)amino]carbonyl]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-55-5 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[2-(trifluoromethyl)phenyl]sulfonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-56-6 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-57-7 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[2-(trifluoromethoxy)phenyl]sulfonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-58-8 CAPLUS
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-59-9 CAPLUS
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-60-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-(methoxythio)phenyl]amino]carbonyl]amino]methylphenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-61-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-bromo-5-methylphenyl]amino]carbonyl]amino]methylphenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-62-4 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-bromo-5-methylphenyl]amino]carbonyl]amino]methylphenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-64-6 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(4-methyl-1-piperazinyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-65-7 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-(4-fluorophenyl)ethyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-66-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-(4-morpholinyl)ethyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-67-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[(2R)-2-pyrrolidinylmethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-68-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[(2S)-2-pyrrolidinylamino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-69-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[(cyclopentylamino)carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-70-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-71-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-72-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-methoxybenzoyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-73-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[([1,1'-biphenyl]-4-ylcarbonyl)amino]methyl]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-74-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[(2-furanylcarbonyl)amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-75-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-76-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[[(2,3-dihydro-5-

benzofuranyl)amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-77-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-78-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-86-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(hexahydro-1H-azepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-87-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-thiazolyl]carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-88-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-89-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyloxy (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-90-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-dichloro-6-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyloxy (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-91-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,5-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyloxy (9CI) (CA INDEX NAME)

onyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-92-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[2-thienylsulfonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-93-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[3-thienylsulfonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-94-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-chlorophenyl)sulfonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-95-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1,3-benzodioxol-5-ylamino)carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-96-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-methoxyphenyl)amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

o)methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-97-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-fluorophenyl)amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-98-6 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[2-(dimethylamino)ethoxy]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-99-7 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-00-3 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-(3-methoxyphenyl)-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625469-01-4 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-(3-ethoxyphenyl)-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-02-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-03-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[2-(ethylamino)ethoxy]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-04-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[3-[5-amino-6-[(3S)-3-piperidinylamino]carbonyl]pyrazinyl]phenoxy]ethyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-05-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(dimethylamino)phenyl]amino]carbonylamino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-06-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-07-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1-(phenylmethyl)-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-08-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-09-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-chlorophenyl)amino]carbonyl]phenyl]-

N-(3S)-3-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-10-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1-(phenylmethyl)-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-11-6 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-12-7 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-[(3S)-hexahydro-1H-azepin-3-yl]-6-(3-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-13-8 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[(2-methylphenyl)acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625469-14-9 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[3-(trifluoromethyl)phenyl]acetyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-15-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[4-(4-methoxyphenyl)acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-16-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[6-methyl-3-pyridinyl]carbonyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-17-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[(3-fluorophenyl)acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-18-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[(3-pyridinylacetyl)amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-19-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[(3-pyridinylcarbonyl)amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-20-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[(2,5-difluorophenyl)acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-21-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[4-(4-fluorophenyl)acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-22-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-23-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(4-nitrophenyl)-2-furanyl]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidiny- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-24-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-(4-nitrophenyl)-2-pyridinyl]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidiny- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-25-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(trifluoromethoxy)phenoxy]acetyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-26-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(5-methyl-3-isoxazolyl)carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-27-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(5-isoxazolylcarbonyl)amino]methyl]phe

nyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-28-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[(1,2,3-thiadiazol-5-ylcarbonyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-29-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,5-dichloro-3-thienyl)carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-30-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(5-chloro-2-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



IT 625469-31-0P 625469-32-1P 625469-33-2P
625469-34-3P 625469-35-4P 625469-36-5P
625469-37-6P 625469-38-7P 625469-39-8P
625469-40-1P 625469-41-2P 625469-42-3P
625469-43-4P 625469-44-5P 625469-45-6P
625469-46-7P 625469-47-8P 625469-48-9P
625469-49-0P 625469-50-3P 625469-51-4P
625469-52-5P 625469-53-6P 625469-54-7P
625469-55-8P 625469-56-9P 625469-57-0P
625469-58-1P 625469-59-2P 625469-60-5P
625469-61-6P 625469-62-7P 625469-63-8P
625469-64-9P 625469-65-0P 625469-66-1P
625469-67-2P 625469-68-3P 625469-69-4P
625469-70-7P 625469-71-8P 625469-72-9P
625469-73-0P 625469-74-1P 625469-75-2P
625469-76-3P 625469-77-4P 625469-78-5P
625469-79-6P 625470-21-5P 625470-22-6P
625471-65-0P 625471-86-5P 625471-88-7P
625478-21-9P 625515-65-3P 625528-57-6P
625614-94-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of protein kinase modulators)

RN 625469-31-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-chloro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-32-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-chloro-6-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 625469-33-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-chloro-2-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-34-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-chloro-2-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 625469-35-4 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-36-5 CAPLUS
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-chloro-2,6-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 625469-37-6 CAPLUS
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625469-38-7 CAPLUS
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-chloro-4-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 625469-39-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-40-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[(2,3,6-trifluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-41-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

(trifluoromethyl)phenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-42-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 625469-43-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-44-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-45-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,5-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-46-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,6-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-47-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(6-chloro-2-fluoro-3-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-48-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-chloro-6-fluoro-3-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 625469-49-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-chloro-3,6-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 625469-50-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,5-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-51-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[(2,3,4-trifluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-52-5 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-53-6 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-fluoro-4-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-54-7 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-chloro-2,6-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625469-55-8 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-56-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-chloro-6-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-57-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,6-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-58-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-59-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-chloro-2-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-60-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-chloro-2-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 625469-61-6 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,6-dimethoxyphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-62-7 CAPLUS
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-bromo-4-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 625469-63-8 CAPLUS
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625469-64-9 CAPLUS
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 625469-65-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[(2,3,5-trifluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-66-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(5-fluoro-2-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-67-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-bromo-5-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 625469-68-3 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(1H-pyrazol-1-yl)phenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-69-4 CAPLUS
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[([1,1'-biphenyl]-3-ylmethyl)amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-70-7 CAPLUS
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625469-71-8 CAPLUS
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,5-dimethylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-72-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,5-dimethylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-73-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-dimethylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-74-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-methoxyphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-75-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-76-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,5-dimethoxyphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-77-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,4-dimethoxyphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-78-5 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-[(3S)-hexahydro-1H-azepin-3-yl]-6-[3-[[[4-(1H-pyrazol-1-yl)phenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625469-79-6 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N,6-diphenyl- (9CI) (CA INDEX NAME)



RN 625470-21-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 625470-22-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-chloro-2,6-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 625471-65-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-1-ethyl-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625471-86-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-(hexahydro-1H-azepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625471-88-7 CAPLUS

Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[2-thienylcarbonyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625478-21-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-difluorophenyl)methyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625515-65-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625528-57-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dihydro-1H-inden-1-yl)amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625614-94-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(2,3-dihydro-1H-inden-2-yl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 625471-19-4 625471-20-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of protein kinase modulators)

RN 625471-19-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-(methoxycarbonyl)phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625471-20-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-(3-aminophenyl)pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 625470-32-8P 625470-92-0P 625470-93-1P
625470-98-6P 625470-99-7P 625471-00-3P
625471-01-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of protein kinase modulators)

RN 625470-32-8 CAPLUS


CN Benzoic acid, 3-[5-amino-6-[(cyclopropylamino)carbonyl]pyrazinyl]- (9CI) (CA INDEX NAME)



RN 625470-92-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-(3-carboxyphenyl)pyrazinyl]carbonyl]amino]-, 1-(1,1-dimethylethyl) ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625470-93-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[1,1'-biphenyl]-2-ylamino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625470-98-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[3-fluoro-4-

(trifluoromethyl)phenyl)methyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625470-99-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(3-chloro-2,6-difluorophenyl)methyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625471-00-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(2-methylphenyl)acetyl]amino]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625471-01-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-(azidomethyl)phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L6 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:42253 CAPLUS
 DOCUMENT NUMBER: 138:106713
 TITLE: Preparation of heterocyclic amines for the treatment of conditions associated with GSK3
 INVENTOR(S): Berg, Stefan; Hellberg, Sven
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
 SOURCE: PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2003004475 | A1 | 20030116 | WO 2002-SE1340 | 20020703 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, | | | | |

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG

AU 2002319989 A1 20030121 AU 2002-319989 20020703
 EP 1406877 A1 20040414 EP 2002-749475 20020703
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 JP 2004536110 T 20041202 JP 2003-510642 20020703
 US 2004186113 A1 20040923 US 2003-481699 20031222
 PRIORITY APPLN. INFO.: SE 2001-2438 A 20010705
 WO 2002-SE1340 W 20020703

OTHER SOURCE(S): MARPAT 138:106713
 GI



AB Title compds. I [Y = carboxamido, amido, sulfonamido, etc.; X = CH, N; P, Q = Ph, 5-6-membered heteroarom. ring, etc.; R1 = halo, NO2, alkyl-CN, alkyl-alkoxy, fluoromethyl, alkyl-amino, etc.; R2 = halo, NO2, CHO, alkyl-nitrile, etc.; n = 0-5; m = 0-4; R14 = H, Me, F, Cl, Br, etc.] are prepared For instance, 3-aminopyridine was reacted with 3-amino-6-bromo-2-pyrazinecarboxylate (DBU) to give II. Example compds. had Ki in the range of 0.001 to 10,000 nM for glycogen synthase kinase-3 (GSK3). I are used for the treatment of Parkinson's Disease, etc.

IT 486424-13-9P, 4-[5-Amino-6-[(pyridin-3-yl)amino]carbonyl]pyrazin-2-yl]benzoic acid 487034-96-8P, 3-Amino-6-(2,4-dichlorophenyl)-N-[4-(2-(pyrrolidin-1-yl)ethyl)pyridin-3-yl]pyrazine-2-carboxamide 487034-97-9P, 3-Amino-6-(3-chloro-4-fluorophenyl)-N-[4-(2-(pyrrolidin-1-yl)ethyl)pyridin-3-yl]pyrazine-2-carboxamide 487035-01-8P, 3-Amino-6-(4-hydroxyphenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of heterocyclic amines for treatment of conditions associated with

gsk-3)


RN 486424-13-9 CAPLUS

CN Benzoic acid, 4-[5-amino-6-[(3-pyridinylamino)carbonyl]pyrazinyl]- (9CI)
(CA INDEX NAME)




RN 487034-96-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(2,4-dichlorophenyl)-N-[4-[2-(1-pyrrolidinyl)ethyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 487034-97-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(3-chloro-4-fluorophenyl)-N-[4-[2-(1-pyrrolidinyl)ethyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 487035-01-8 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-(4-hydroxyphenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)



IT 487034-72-0P, 3-Amino-6-phenyl-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-73-1P, 3-Amino-6-(2-methylphenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-74-2P, 3-Amino-6-(4-cyanophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-75-3P, 3-Amino-6-(3,4-methylenedioxyphenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-77-5P, 3-Amino-6-(3-nitrophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-78-6P, 3-Amino-6-(3,5-bis(trifluoromethyl)phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-82-2P, 3-Amino-6-(4-fluorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-83-3P, 3-Amino-6-(4-chlorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-84-4P, 3-Amino-6-(2,3-dichlorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-85-5P, 3-Amino-6-(2,4-dichlorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-86-6P, 3-Amino-6-(2,4-difluorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-87-7P, 3-Amino-6-(3,4-difluorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-88-8P, 3-Amino-6-(3-chloro-4-fluorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-90-2P, 3-Amino-6-(4-fluoro-3-methylphenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-91-3P, 3-Amino-6-(3,4-dimethylphenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-92-4P, 3-Amino-6-(3-fluorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-93-5P, 3-Amino-6-(2-fluorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-98-0P, 3-Amino-6-(2,4-dichlorophenyl)-N-[4-(2-(pyrrolidin-1-yl)ethyl)pyridin-3-yl]pyrazine-2-carboxamide hydrochloride 487034-99-1P, 3-Amino-6-(3-chloro-4-fluorophenyl)-N-[4-(2-(pyrrolidin-1-yl)ethyl)pyridin-3-yl]pyrazine-2-carboxamide hydrochloride 487035-02-9P, 3-Amino-6-(4-hydroxyphenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide hydrochloride 487035-03-0P, 3-Amino-6-[4-(aminocarbonyl)phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of heterocyclic amines for treatment of conditions associated with gsk-3)

RN 487034-72-0 CAPLUS
 CN 2-Pyrazinecarboxamide, 3-amino-6-phenyl-N-3-pyridinyl- (CA INDEX NAME)




RN 487034-73-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(2-methylphenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-74-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(4-cyanophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-75-3 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-(1,3-benzodioxol-5-yl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-77-5 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-(3-nitrophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 487034-78-6 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3,5-bis(trifluoromethyl)phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-82-2 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-(4-fluorophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-83-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(4-chlorophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-84-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(2,3-dichlorophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-85-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(2,4-dichlorophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-86-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(2,4-difluorophenyl)-N-3-pyridinyl- (9CI)
(CA INDEX NAME)




RN 487034-87-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(3,4-difluorophenyl)-N-3-pyridinyl- (9CI)
(CA INDEX NAME)




RN 487034-88-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(3-chloro-4-fluorophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-90-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(4-fluoro-3-methylphenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-91-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(3,4-dimethylphenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-92-4 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-(3-fluorophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 487034-93-5 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-(2-fluorophenyl)-N-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 487034-98-0 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-(2,4-dichlorophenyl)-N-[4-[2-(1-pyrrolidinyl)ethyl]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 487034-99-1 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-(3-chloro-4-fluorophenyl)-N-[4-[2-(1-pyrrolidinyl)ethyl]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 487035-02-9 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-(4-hydroxyphenyl)-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 487035-03-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-(aminocarbonyl)phenyl]-N-3-pyridinyl-, (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:42250 CAPLUS
 DOCUMENT NUMBER: 138:106712
 TITLE: Preparation of pyrazine-2-carboxamides as glycogen synthase kinase-3 (GSK3) inhibitors
 INVENTOR(S): Berg, Stefan; Hellberg, Sven
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
 SOURCE: PCT Int. Appl., 158 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 2003004472 | A1 | 20030116 | WO 2002-SE1339 | 20020703 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2452686 | A1 | 20030116 | CA 2002-2452686 | 20020703 |
| AU 2002318099 | A1 | 20030121 | AU 2002-318099 | 20020703 |
| EP 1414801 | A1 | 20040506 | EP 2002-747795 | 20020703 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | |
| BR 2002010838 | A | 20040713 | BR 2002-10838 | 20020703 |
| CN 1551869 | A | 20041201 | CN 2002-813545 | 20020703 |
| JP 2005505515 | T | 20050224 | JP 2003-510640 | 20020703 |
| HU 2005000339 | A2 | 20050728 | HU 2005-339 | 20020703 |
| IN 2003MN011143 | A | 20060505 | IN 2003-MN1143 | 20031215 |
| MX 2003PA11972 | A | 20040326 | MX 2003-PA11972 | 20031218 |
| US 2006052396 | A1 | 20060309 | US 2003-481721 | 20031222 |
| ZA 2003009977 | A | 20050323 | ZA 2003-9977 | 20031223 |
| NO 2004000014 | A | 20040302 | NO 2004-14 | 20040102 |
| PRIORITY APPLN. INFO.: | | | SE 2001-2439 | A 20010705 |

OTHER SOURCE(S):

MARPAT 138:106712

GI



II

AB The title compds. [I; Z = CH, N; Y = CONR⁵, NR⁵CO, SO₂NR⁵, etc.; X = CH, N; P = Ph or 5-6 membered heteroaryl which may optionally be fused with 5-6 membered (un)saturated ring containing one or more atoms selected from C,

N, O

or S; Q = Ph or 5-6 membered heteroaryl containing one or more heteroatoms selected from N, O or S of which at least one atom is selected from N atom; R = CHO, OCH₂F, OCH₂F₂, OCF₃, etc.; R₃, R₄ = halo, NO₂, CHO, etc.; n, m = 0-4], useful in the prevention and/or treatment of conditions associated with glycogen synthase kinase-3, were prepared and formulated. Thus, coupling 3-amino-6-bromo-N-(pyridin-3-yl)pyrazine-2-carboxamide with 4-(pyrrolidin-1-ylsulfonyl)phenylboronic acid (prepn. given) in the presence of Pd(dppf)Cl₂ and Na₂CO₃ in dimethoxyethane afforded 93% the carboxamide II. Typical K_i values for the compds. I are in the range of about 0.001 to about 10,000 nM.


IT 486423-10-3P, 3-Amino-N-(pyridin-3-yl)-6-[4-((pyrrolidin-1-yl)sulfonyl)phenyl]pyrazine-2-carboxamide 486423-11-4P, 3-Amino-6-[4-((piperidin-1-yl)sulfonyl)phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-12-5P, 3-Amino-6-[3-ethyl-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-13-6P, 3-Amino-6-[4-[(4-methylpiperazin-1-yl)sulfonyl]-3-(trifluoromethoxy)phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-15-8P, 3-Amino-N-[5-[3-(dimethylamino)propyl]pyridin-3-yl]-6-[4-(piperidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide 486424-07-1P 486424-20-8P

RL: CPS (Chemical process); PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)


(preparation of pyrazine-2-carboxamides as glycogen synthase kinase-3 (GSK3) inhibitors)

RN 486423-10-3 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-(1-pyrrolidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 486423-11-4 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[4-(1-piperidinylsulfonyl)phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 486423-12-5 CAPLUS
 CN 2-Pyrazinecarboxamide, 3-amino-6-[3-ethyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (CA INDEX NAME)




RN 486423-13-6 CAPLUS
 CN 2-Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]-3-(trifluoromethoxy)phenyl]-N-3-pyridinyl- (CA INDEX NAME)




RN 486423-15-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[5-[3-(dimethylamino)propyl]-3-pyridinyl]-6-[(1-piperidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 486424-07-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[(2-aminoethyl)amino]sulfonyl]-3-(trifluoromethoxy)phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-20-8 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



IT 486423-14-7P, tert-Butyl 4-[(4-[5-amino-6-((3-pyridin-3-yl)amino)carbonyl)pyrazin-2-yl]phenyl)sulfonyl]piperazine-1-carboxylate
 486423-78-3P 486423-80-7P 486424-13-9P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrazine-2-carboxamides as glycogen synthase kinase-3 (GSK3) inhibitors)
 RN 486423-14-7 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[4-[5-amino-6-[(3-pyridinylamino)carbonyl]pyrazinyl]phenyl)sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 486423-78-3 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[4-[5-amino-6-[(3-pyridinylamino)carbonyl]pyrazinyl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 486423-80-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[4-[5-amino-6-[(3-pyridinylamino)carbonyl]pyrazinyl]-2,5-difluorophenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 486424-13-9 CAPLUS

CN Benzoic acid, 4-[5-amino-6-[(3-pyridinylamino)carbonyl]pyrazinyl]- (9CI)
(CA INDEX NAME)



IT 486423-16-9P, 3-Amino-N-[5-[3-(dimethylamino)propyl]pyridin-3-yl]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide
486423-17-0P, 3-Amino-N-[4-[(dimethylamino)methyl]pyridin-3-yl]-6-[4-[(dimethylamino)sulfonyl]phenyl]pyrazine-2-carboxamide
486423-18-1P, 3-Amino-N-[4-[3-(dimethylamino)propyl]pyridin-3-yl]-6-[4-[(dimethylamino)sulfonyl]phenyl]pyrazine-2-carboxamide
486423-19-2P, 3-Amino-6-(4-[[N-methyl-N-(1-methylpyrrolidin-3-yl)amino]sulfonyl]phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide
486423-20-5P, 3-Amino-6-(4-[[N-methyl-N-(1-methylpiperidin-4-yl)amino]sulfonyl]phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide
486423-21-6P, 3-Amino-6-(4-[[N-[3-(dimethylamino)propyl]-N-methylamino]sulfonyl]phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide
hydrochloride 486423-22-7P, 3-Amino-6-(4-[[3-(dimethylamino)pyrrolidin-1-yl]sulfonyl]phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide
486423-23-8P, 3-Amino-6-[4-[(morpholin-4-yl)sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide
486423-24-9P 486423-25-0P, 3-Amino-6-[4-[(4-ethylpiperazine-1-yl)sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide
486423-26-1P 486423-27-2P
486423-28-3P 486423-29-4P, 3-Amino-6-[4-[[N-isopropyl-N-

(2-methoxyethyl)amino)sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide hydrochloride 486423-30-7P 486423-31-8P
486423-32-9P, 3-Amino-N-(pyridin-3-yl)-6-(4-[[2-(pyridin-2-yl)ethyl]amino)sulfonyl]phenyl)pyrazine-2-carboxamide 486423-33-0P,
3-Amino-6-(4-[[2-(2-methoxy-1-methylethyl)amino)sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide hydrochloride 486423-34-1P,
3-Amino-6-[4-[[2-(dimethylamino)-1-methylethyl]amino)sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-35-2P,
3-Amino-N-(pyridin-3-yl)-6-(4-[[3-(pyrrolidin-1-yl)propyl]amino)sulfonyl]phenyl)pyrazine-2-carboxamide
486423-36-3P, 6-[4-[(4-Acetylpiperazin-1-yl)sulfonyl]phenyl]-3-amino-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-37-4P
486423-38-5P 486423-40-9P, 3-Amino-6-(4-[[N-[2-(dimethylamino)ethyl]-N-ethylamino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-41-0P, 3-Amino-6-(4-[[N-[3-(dimethylamino)propyl]-N-methylamino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-42-1P, 3-Amino-6-(4-[[3-(dimethylamino)propyl]amino]carbonyl]phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-43-2P, 3-Amino-N-(pyridin-3-yl)-6-(4-[[2-(pyrrolidin-1-yl)ethyl]amino]carbonyl]phenyl)pyrazine-2-carboxamide 486423-44-3P, 3-Amino-N-(pyridin-3-yl)-6-(4-[[3-(pyrrolidin-1-yl)propyl]amino]carbonyl]phenyl)pyrazine-2-carboxamide 486423-45-4P, 3-Amino-6-[4-[(4-methyl-1,4-diazepan-1-yl)carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-46-5P, 3-Amino-6-[4-[[N-methyl-N-(1-methylpyrrolidin-3-yl)amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-47-6P, 3-Amino-6-[4-[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-48-7P, 3-Amino-6-[4-[[2-(dimethylamino)-1-methylethyl]amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-49-8P, 3-Amino-6-[4-[[3-(dimethylamino)pyrrolidin-1-yl]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-50-1P, 3-Amino-6-[4-[[1-(1-ethylpyrrolidin-2-yl)methyl]amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-51-2P, 3-Amino-6-[4-[[3-(4-methylpiperazin-1-yl)propyl]amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-52-3P, 3-Amino-6-(4-[[N-methyl-N-(1-methylpiperidin-4-yl)amino]carbonyl]phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-53-4P, 3-Amino-6-(4-[[2-(piperidin-1-yl)ethyl]amino]carbonyl]phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-54-5P, 3-Amino-6-(4-[[1-(1-ethylpiperidin-3-yl)amino]carbonyl]phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-55-6P, 3-Amino-6-[4-[[2-(1-methylpyrrolidin-2-yl)ethyl]amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-56-7P, 3-Amino-N-(pyridin-3-yl)-6-[4-[[4-(pyrrolidin-1-yl)piperidin-1-yl]carbonyl]phenyl]pyrazine-2-carboxamide 486423-58-9P 486423-59-0P 486423-60-3P 486423-61-4P 486423-62-5P 486423-63-6P 486423-64-7P 486423-65-8P 486423-66-9P 486423-67-0P 486423-68-1P 486423-69-2P 486423-70-5P, 3-Amino-6-[4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-71-6P, 3-Amino-6-[4-[[2-(4-morpholinyl)ethyl]amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-72-7P, 3-Amino-6-[4-[[1-(1-methylpyrrolidin-3-yl)oxy]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-73-8P 486423-74-9P 486423-75-0P 486423-76-1P 486423-77-2P 486423-79-4P 486423-81-8P 486423-82-9P 486423-83-0P 486423-84-1P 486423-88-5P 486423-89-6P 486423-90-9P 486423-91-0P 486423-92-1P 486423-93-2P 486423-94-3P 486423-95-4P 486423-96-5P 486423-97-6P 486423-98-7P 486423-99-8P 486424-00-4P


486424-01-5P 486424-04-8P 486424-05-9P
 486424-06-0P 486424-08-2P 486424-09-3P
 486424-12-8P 486424-14-0P, 3-Amino-6-[4-
 [(dimethylamino)sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide
 486424-15-1P, 3-Amino-6-[3-[(dimethylamino)sulfonyl]phenyl]-N-
 (pyridin-3-yl)pyrazine-2-carboxamide 486424-16-2P,
 3-Amino-6-[2-[(dimethylamino)sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-
 carboxamide 486424-17-3P, 3-Amino-6-[4-(aminosulfonyl)phenyl]-N-
 (pyridin-3-yl)pyrazine-2-carboxamide 486424-19-5P,
 3-Amino-6-[4-[(3-(morpholin-4-yl)propyl)amino)sulfonyl]phenyl]-N-(pyridin-
 3-yl)pyrazine-2-carboxamide 486424-21-9P 486424-22-0P,
 3-Amino-6-[2,5-difluoro-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-N-
 (pyridin-3-yl)pyrazine-2-carboxamide 486424-23-1P,
 3-Amino-6-[3-fluoro-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-N-(pyridin-
 3-yl)pyrazine-2-carboxamide 486424-24-2P, 3-Amino-6-[3-methyl-4-
 [(4-methylpiperazin-1-yl)sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-
 carboxamide 486424-25-3P, 3-Amino-6-[2-[(4-methylpiperazin-1-
 yl)sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide
 486424-26-4P, 3-Amino-6-[3-[(4-methylpiperazin-1-
 yl)sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide
 486424-27-5P, 3-Amino-6-[2-methyl-4-[(4-methylpiperazin-1-
 yl)sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide
 486424-28-6P, 3-Amino-6-[4-[(2-(dimethylamino)ethyl)amino]sulfonyl]-
 3-(trifluoromethoxy)phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide
 486424-29-7P, 3-Amino-6-[4-[N-[2-(dimethylamino)ethyl]-N-
 ethylamino]sulfonyl]-3-(trifluoromethoxy)phenyl]-N-(pyridin-3-yl)pyrazine-
 2-carboxamide 486424-30-0P, 3-Amino-6-[4-[(4-methylpiperazin-1-
 yl)sulfonyl]-2-(trifluoromethyl)phenyl]-N-(pyridin-3-yl)pyrazine-2-
 carboxamide 486424-31-1P, 3-Amino-6-[4-[2-
 (dimethylamino)ethoxy]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide
 486424-32-2P, 3-Amino-6-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-
 (pyridin-3-yl)pyrazine-2-carboxamide 486424-33-3P,
 3-Amino-6-[4-[N-[2-(dimethylamino)ethyl]-N-methylamino]carbonyl]phenyl]-N-
 (pyridin-3-yl)pyrazine-2-carboxamide 486424-34-4P,
 3-Amino-6-[2,5-difluoro-4-[(pyrrolidin-1-yl)sulfonyl]phenyl]-N-[5-(3-
 (pyrrolidin-1-yl)propyl)pyridin-3-yl]pyrazine-2-carboxamide
 486424-40-2P, tert-Butyl [2-[[4-[5-amino-6-[(pyridin-3-
 yl)amino]carbonyl]pyrazin-2-yl]phenyl)sulfonyl]-N-(tert-
 butoxycarbonyl)amino]ethyl]carbamate 486424-41-3P
 486424-42-4P 486424-43-5P, 3-Amino-6-[2-fluoro-4-[(4-
 methylpiperazin-1-yl)sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-
 carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyrazine-2-carboxamides as glycogen synthase kinase-3 (GSK3)
 inhibitors)


RN 486423-16-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[5-[3-(dimethylamino)propyl]-3-pyridinyl]-6-
 [4-(1-pyrrolidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 486423-17-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[4-[(dimethylamino)methyl]-3-pyridinyl]-6-[4-[(dimethylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 486423-18-1 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-[4-[3-(dimethylamino)propyl]-3-pyridinyl]-6-[4-[(dimethylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 486423-19-2 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[methyl(1-methyl-3-

pyrrolidinyl)amino)sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-20-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[methyl(1-methyl-4-piperidinyl)amino]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 486423-21-6 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[[[3-(dimethylamino)propyl]methylamino]sulfonyl]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 486423-22-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[3-(dimethylamino)-1-pyrrolidinyl]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-23-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-(4-morpholinylsulfonyl)phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 486423-24-9 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[[[3-(4-methyl-1-piperazinyl)propyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 486423-25-0 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[4-[(4-ethyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (CA INDEX NAME)



RN 486423-26-1 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-[[[2-(1-pyrrolidinyl)ethyl]amino]sulfonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 486423-27-2 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 486423-28-3 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)propyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 486423-29-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(methoxyethyl)(1-methylethyl)amino]sulfonyl]phenyl]-N-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 486423-30-7 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[4-[[[(1-ethyl-2-pyrrolidinyl)methyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 486423-31-8 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(diethylamino)ethyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 486423-32-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-[[2-(2-pyridinyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 486423-33-0 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[[2-methoxy-1-methylethyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 486423-34-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)-1-methylethyl]amino]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-35-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-[[[3-(1-pyrrolidinyl)propyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 486423-36-3 CAPLUS

CN Pyrazinecarboxamide, 6-[4-[(4-acetyl-1-piperazinyl)sulfonyl]phenyl]-3-amino-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 486423-37-4 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)ethyl]ethylamino]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 486423-38-5 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[[[3-(dimethylamino)propyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 486423-40-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)ethyl]ethylamino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-41-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[3-(dimethylamino)propyl]methylamino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-42-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[3-(dimethylamino)propyl]amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-43-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 486423-44-3 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-[[[3-(1-pyrrolidinyl)propyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 486423-45-4 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-

yl)carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-46-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[methyl(1-methyl-3-pyrrolidinyl)amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 486423-47-6 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 486423-48-7 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)-1-

methylethylamino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-49-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[3-(dimethylamino)-1-pyrrolidinyl]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-50-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[1-ethyl-2-pyrrolidinyl)methyl]amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-51-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-52-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[methyl(1-methyl-4-piperidinyl)amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-53-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(1-piperidinyl)ethyl]amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-54-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[1-(1-ethyl-3-piperidinyl)amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-55-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-56-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-[[4-(1-pyrrolidinyl)-1-piperidinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 486423-58-9 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 486423-59-0 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-fluoro-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 486423-60-3 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[3-methyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 486423-61-4 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[2-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 486423-62-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 486423-63-6 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[2-methyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 486423-64-7 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)ethyl]amino]sulfonyl]-3-(trifluoromethoxy)phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 486423-65-8 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)ethyl]ethylamino]sulfonyl]-3-(trifluoromethoxy)phenyl]-N-3-pyridinyl-, hydrochloride (9CI)
 (CA INDEX NAME)




●x HCl

RN 486423-66-9 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[4-[[[4-methyl-1-piperazinyl]sulfonyl]-2-(trifluoromethyl)phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 486423-67-0 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[4-[2-(dimethylamino)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 486423-68-1 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 486423-69-2 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)ethyl]methylamino]carbonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 486423-70-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 486423-71-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(4-morpholinyl)ethyl]amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-72-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-73-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[2-fluoro-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 486423-74-9 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[5-fluoro-2-methyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 486423-75-0 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[2,5-dimethyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-76-1 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-77-2 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-79-4 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-81-8 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-82-9 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-[2-(1-pyrrolidinyloxy)phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-83-0 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[2,6-dimethyl-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 486423-84-1 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[2-methyl-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 486423-88-5 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[4-(1-pyrrolidinylmethyl)-3-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 486423-89-6 CAPLUS
CN Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-(1-pyrrolidinylsulfonyl)phenyl]-N-[4-[2-(1-pyrrolidinyl)ethyl]-3-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 486423-90-9 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-(1-pyrrolidinylsulfonyl)phenyl]-N-[5-[3-(1-pyrrolidinyl)propyl]-3-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 486423-91-0 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-(1-piperidinylsulfonyl)phenyl]-N-[5-[3-(1-pyrrolidinyl)propyl]-3-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● x HCl

RN 486423-92-1 CAPLUS
CN Pyrazinecarboxamide, 3-amino-6-[4-(1-piperidinylsulfonyl)phenyl]-N-[5-[3-(1-pyrrolidinyl)propyl]-3-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● x HCl


RN 486423-93-2 CAPLUS
CN Pyrazinecarboxamide, 3-amino-N-[5-[3-(1-pyrrolidinyl)propyl]-3-pyridinyl]-
6-[4-(1-pyrrolidinylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX
NAME)



● x HCl

RN 486423-94-3 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-[4-[2-(1-pyrrolidinyl)ethyl]-3-pyridinyl]-6-[4-(1-pyrrolidinylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 486423-95-4 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-[4-[3-(1-pyrrolidinyl)propyl]-3-pyridinyl]-6-[4-(1-pyrrolidinylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 486423-96-5 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-[4-(1-pyrrolidinylmethyl)-3-pyridinyl]-6-[4-(1-pyrrolidinylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 486423-97-6 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-[4-[(dimethylamino)methyl]-3-pyridinyl]-6-[4-(1-pyrrolidinylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 486423-98-7 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-[4-[(dimethylamino)methyl]-3-pyridinyl]-6-[4-(1-piperidinylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 486423-99-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-ethyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 486424-00-4 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]-3-(trifluoromethoxy)phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 486424-01-5 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-6-[4-[(2-aminoethylamino)sulfonyl]-3-(trifluoromethoxy)phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 486424-04-8 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-(1-pyrrolidinylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 486424-05-9 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-(1-piperidinylsulfonyl)phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 486424-06-0 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-(1-piperazinylsulfonyl)phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 486424-08-2 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[2-(1-piperazinyl)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 486424-09-3 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-[2-(1-piperazinyl)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 486424-12-8 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-[5-[3-(dimethylamino)propyl]-3-pyridinyl]-6-[4-(1-piperidinylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 486424-14-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[(dimethylamino)sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 486424-15-1 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[(dimethylamino)sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 486424-16-2 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[2-[(dimethylamino)sulfonyl]phenyl]-N-3-

pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-17-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-(aminosulfonyl)phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-19-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[3-(4-morpholinyl)propyl]amino]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 486424-21-9 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[[[3-(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 486424-22-0 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (CA INDEX NAME)




RN 486424-23-1 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[3-fluoro-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (CA INDEX NAME)




RN 486424-24-2 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[3-methyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (CA INDEX NAME)




RN 486424-25-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[2-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-26-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-27-5 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[2-methyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (CA INDEX NAME)




RN 486424-28-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)ethyl]amino]sulfonyl]-3-(trifluoromethoxy)phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-29-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)ethyl]amino]sulfonyl]-3-(trifluoromethoxy)phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-30-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]-2-(trifluoromethyl)phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-31-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[2-(dimethylamino)ethoxy]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-32-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-33-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[2-(dimethylamino)ethyl]methylamino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-34-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-(1-pyrrolidinylsulfonyl)phenyl]-N-[5-[3-(1-pyrrolidinyl)propyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 486424-40-2 CAPLUS

CN Carbamic acid, [[4-[5-amino-6-[(3-pyridinylamino)carbonyl]pyrazinyl]phenyl]sulfonyl][2-[[1,1-dimethylethoxy]carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 486424-41-3 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 486424-42-4 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 486424-43-5 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[2-fluoro-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (CA INDEX NAME)




IT 486422-09-7P, 3-Amino-6-[4-[[2-(dimethylamino)ethyl]amino]sulfonyl]phenyl]-N-pyridin-3-ylpyrazine-2-carboxamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazine-2-carboxamides as glycogen synthase kinase-3 (GSK3) inhibitors)

RN 486422-09-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[2-(dimethylamino)ethyl]amino]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold
COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 50.97 | 230.92 |

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| -7.20 | -7.20 |

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:31:45 ON 21 JAN 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

| | | |
|---------|--------|---|
| NEWS 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS 2 | MAR 31 | IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats |
| NEWS 3 | MAR 31 | CAS REGISTRY enhanced with additional experimental spectra |
| NEWS 4 | MAR 31 | CA/Caplus and CASREACT patent number format for U.S. applications updated |
| NEWS 5 | MAR 31 | LDPCI now available as a replacement to LDPCI |
| NEWS 6 | MAR 31 | EMBASE, EMBAL, and LEMBASE reloaded with enhancements |
| NEWS 7 | APR 04 | STN AnaVist, Version 1, to be discontinued |
| NEWS 8 | APR 15 | WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats |
| NEWS 9 | APR 28 | EMBASE Controlled Term thesaurus enhanced |
| NEWS 10 | APR 28 | IMSRESEARCH reloaded with enhancements |

NEWS 11 MAY 30 INPAFAMDB now available on STN for patent family searching

NEWS 12 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option

NEWS 13 JUN 06 EPFULL enhanced with 260,000 English abstracts

NEWS 14 JUN 06 KOREAPAT updated with 41,000 documents

NEWS 15 JUN 13 USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications

NEWS 16 JUN 19 CAS REGISTRY includes selected substances from web-based collections

NEWS 17 JUN 25 CA/CAPLUS and USPAT databases updated with IPC reclassification data

NEWS 18 JUN 30 AEROSPACE enhanced with more than 1 million U.S. patent records

NEWS 19 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations

NEWS 20 JUN 30 STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in

NEWS 21 JUN 30 STN AnaVist enhanced with database content from EPFULL

NEWS 22 JUL 28 CA/CAPLUS patent coverage enhanced

NEWS 23 JUL 28 EPFULL enhanced with additional legal status information from the epoline Register

NEWS 24 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements

NEWS 25 JUL 28 STN Viewer performance improved

NEWS 26 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced

NEWS 27 AUG 13 CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998

NEWS 28 AUG 15 CAOLD to be discontinued on December 31, 2008

NEWS 29 AUG 15 CAPLUS currency for Korean patents enhanced

NEWS 30 AUG 25 CA/CAPLUS, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:59:37 ON 26 AUG 2008

| | | |
|----------------------|------------|---------|
| => file registry | | |
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 15:00:02 ON 26 AUG 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 AUG 2008 HIGHEST RN 1043631-35-1
DICTIONARY FILE UPDATES: 25 AUG 2008 HIGHEST RN 1043631-35-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10 series\10539546\10539546c.str



chain nodes :
7 14 15 16
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13 17 18 19 20 21 22
chain bonds :
2-8 5-7 6-14 14-15 14-16 15-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 17-18 17-22
18-19 19-20 20-21 21-22
exact/norm bonds :
5-7 14-15 14-16 15-17
exact bonds :
2-8 6-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 17-18 17-22
18-19 19-20 20-21 21-22

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 15:00:21 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 43 TO ITERATE

100.0% PROCESSED 43 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 467 TO 1253

PROJECTED ANSWERS: 1 TO 80


L2 1 SEA SSS SAM L1

=> d scan

L2 1 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 2-Pyrazinecarboxamide, 3-amino-6-(4-methoxyphenyl)-N-phenyl-

MF C18 H16 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 full

FULL SEARCH INITIATED 15:00:36 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 826 TO ITERATE

100.0% PROCESSED 826 ITERATIONS

25 ANSWERS

SEARCH TIME: 00.00.01

L3 25 SEA SSS FUL L1


=> d scan

L3 25 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 2-Pyrazinecarboxamide, 3-amino-N-(3-cyanophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-

MF C23 H23 N7 O3 S

CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L3 25 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN


IN 2-Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[3-(trifluoromethyl)phenyl]-, hydrochloride

(1:1)
MF C23 H23 F3 N6 O3 S . Cl H



● HCl

L3 25 ANSWERS REGISTRY COPYRIGHT 2008 ACS ON STN
IN 2-Pyrazinecarboxamide, 3-amino-N-[2-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-
1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1)
MF C23 H25 N7 O4 S . Cl H



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 178.82 | 179.03 |

FILE 'CAPLUS' ENTERED AT 15:01:06 ON 26 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Aug 2008 VOL 149 ISS 9
FILE LAST UPDATED: 25 Aug 2008 (20080825/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l3

L4 3 L3

=> d l4 1-3 ibib hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:759828 CAPLUS

DOCUMENT NUMBER: 141:260774

TITLE: Preparation of pyrazinecarboxamide compounds as inhibitors of transforming growth factor (TGF) signaling pathway

INVENTOR(S): Munchhof, Michael J.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 26 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------------|--|----------|-----------------|----------|
| US 20040180905 | A1 | 20040916 | US 2004-798198 | 20040310 |
| US 7199123 | B2 | 20070403 | | |
| CA 2517720 | A1 | 20040923 | CA 2004-2517720 | 20040223 |
| WO 2004080982 | A1 | 20040923 | WO 2004-IB581 | 20040223 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| EP 1606267 | A1 | 20051221 | EP 2004-713617 | 20040223 |

EP 1606267 B1 20080730
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2004008251 A 20060301 BR 2004-8251 20040223
 JP 2006519833 T 20060831 JP 2006-506288 20040223
 PRIORITY APPLN. INFO.: US 2003-453784P P 20030311
 WO 2004-IB581 W 20040223
 OTHER SOURCE(S): MARPAT 141:260774
 IT 625469-79-6P 756521-87-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of pyrazinecarboxamides as inhibitors of TGF- β signaling
 pathway)
 RN 625469-79-6 CAPLUS
 CN 2-Pyrazinecarboxamide, 3-amino-N,6-diphenyl- (CA INDEX NAME)



RN 756521-87-6 CAPLUS
 CN 2-Pyrazinecarboxamide, 3-amino-6-(4-methoxyphenyl)-N-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:534194 CAPLUS
 DOCUMENT NUMBER: 141:89114
 TITLE: Preparation of novel 3-aminopyrazine-2-carboxamides having selective inhibiting effect at GSK3
 INVENTOR(S): Berg, Stefan; Hellberg, Sven
 PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Soederman, Peter
 SOURCE: PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2004055006 | A1 | 20040701 | WO 2003-SE1956 | 20031215 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003287/136 A1 20040709 AU 2003-287/136 20031215
 EP 1575939 A1 20050921 EP 2003-781205 20031215
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006516124 T 20060622 JP 2004-560224 20031215
 US 20060173014 A1 20060803 US 2005-539546 20050616
 PRIORITY APPLN. INFO.: SE 2002-3752 A 20021217
 WO 2003-SE1956 W 20031215

OTHER SOURCE(S): MARPAT 141:89114


IT 714237-14-6P 714237-16-8P 714237-17-9P
 714237-18-0P 714237-19-1P 714237-20-4P
 714237-21-5P 714237-22-6P 714237-32-8P
 714237-33-9P 714237-34-0P 714237-35-1P
 714237-36-2P 714237-43-1P 714237-47-5P
 714237-48-6P 714237-49-7P 714237-50-0P
 714237-51-1P 714237-52-2P 714237-57-7P
 714237-58-8P 714237-68-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel 3-aminopyrazine-2-carboxamides having selective inhibiting effect at GSK3)


RN 714237-14-6 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(3-nitrophenyl)-6-[4-(1-pyrrolidinylsulfonyl)phenyl]- (CA INDEX NAME)



RN 714237-16-8 CAPLUS


CN 2-Pyrazinecarboxamide, 3-amino-N-(2-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 714237-17-9 CAPLUS


CN 2-Pyrazinecarboxamide, 3-amino-N-(4-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 714237-18-0 CAPLUS


CN 2-Pyrazinecarboxamide, 3-amino-N-[2-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 714237-19-1 CAPLUS


CN 2-Pyrazinecarboxamide, 3-amino-N-[3-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 714237-20-4 CAPLUS


CN 2-Pyrazinecarboxamide, 3-amino-N-(3-cyanophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 714237-21-5 CAPLUS


CN 2-Pyrazinecarboxamide, 3-amino-N-(2-bromophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 714237-22-6 CAPLUS


CN 2-Pyrazinecarboxamide, 3-amino-N-(3-bromophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 714237-32-8 CAPLUS


CN 2-Pyrazinecarboxamide, 3-amino-N-(3-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 714237-33-9 CAPLUS


CN 2-Pyrazinecarboxamide, N-(3-acetylphenyl)-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 714237-34-0 CAPLUS


CN 2-Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[3-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 714237-35-1 CAPLUS

CN 2-Pyrazinecarboxamide, N-[3-(acetylaminophenyl)]-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 714237-36-2 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-[3-(aminosulfonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 714237-43-1 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(3-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 714237-47-5 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(4-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 714237-48-6 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-[2-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 714237-49-7 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-[3-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 714237-50-0 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(3-cyanophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 714237-51-1 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(2-bromophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 714237-52-2 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(3-bromophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 714237-57-7 CAPLUS

CN 2-Pyrazinecarboxamide, N-(3-acetylphenyl)-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 714237-58-8 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 714237-68-0 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(2-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:892800 CAPLUS

DOCUMENT NUMBER: 139:395950

TITLE: Preparation of substituted pyrazines as protein kinase

modulators

INVENTOR(S): Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepf, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Timothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 468 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|--|----------|-----------------|------------|
| WO 2003093297 | A2 | 20031113 | WO 2003-US13869 | 20030502 |
| WO 2003093297 | A3 | 20040701 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2484209 | A1 | 20031113 | CA 2003-2484209 | 20030502 |
| AU 2003234464 | A1 | 20031117 | AU 2003-234464 | 20030502 |
| EP 1501514 | A2 | 20050202 | EP 2003-728690 | 20030502 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| JP 2005530760 | T | 20051013 | JP 2004-501436 | 20030502 |
| US 20060211709 | A1 | 20060921 | US 2005-513081 | 20050727 |
| PRIORITY APPLN. INFO.: | | | US 2002-377933P | P 20020503 |
| | | | WO 2003-US13869 | W 20030502 |
| OTHER SOURCE(S): | MARPAT 139:395950 | | | |
| IT 625469-79-6P | | | | |
| RL: | PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | |
| | (preparation of protein kinase modulators) | | | |
| RN 625469-79-6 | CAPLUS | | | |
| CN 2-Pyrazinecarboxamide, 3-amino-N,6-diphenyl- | (CA INDEX NAME) | | | |



=> log hold
COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 20.37 | 199.40 |

FULL ESTIMATED COST

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 15:12:29 ON 26 AUG 2008